Gland Pharma share price: Revenue from operations fell 10% year-on-year to Rs 1,384 crore. EBITDA increased by 1% year-on-year to Rs 360 crore, with margins improving by 300 basis points to 26%. R&D expenses were Rs 43.7 crore, making up 4.3% of the revenue.
Positive Breakout: These 3 stocks cross above their 200 DMAs
In the NSE Midcap pack, three stocks’ close prices crossed above their 200 DMA (Daily Moving Averages) on February 5, according to stockedge.com’s technical scan
February 6, 2025